Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 81445 pertains to a genomic sequence analysis panel specifically designed for solid organ neoplasms. This panel involves the molecular genetic testing of a tumor sample to identify sequence variants and copy number variants across a range of 5 to 50 genes. The genes included in this analysis may encompass critical oncogenes and tumor suppressor genes such as ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, and RET. The primary objective of this testing is to provide insights into the genetic alterations present in the tumor, which can significantly influence treatment decisions following a cancer diagnosis. By understanding the molecular characteristics of the tumor, healthcare providers can tailor treatment strategies that are more likely to be effective based on the specific genetic pathways involved. The testing process may involve various methodologies, including next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), pyrosequencing, quantitative PCR, and DNA/RNA fragment analysis. These advanced techniques enable the detection of a wide array of mutations, such as base substitutions, duplications, deletions, and rearrangements, thereby enhancing the precision of cancer treatment.
© Copyright 2026 Coding Ahead. All rights reserved.
The genomic sequence analysis panel represented by CPT® Code 81445 is indicated for the evaluation of solid organ neoplasms. This testing is performed to identify specific genetic alterations that may influence treatment decisions in patients diagnosed with cancer. The following conditions and symptoms may warrant the use of this genomic analysis:
The procedure for conducting the genomic sequence analysis panel under CPT® Code 81445 involves several critical steps to ensure accurate results. The following outlines the procedural steps:
After the genomic sequence analysis is completed, the results are typically reviewed by a healthcare provider who specializes in oncology or genetics. The findings can provide valuable insights into the tumor's molecular profile, which can guide treatment decisions. Patients may be monitored for any side effects or complications related to the biopsy procedure. Additionally, the healthcare team may discuss the implications of the genetic findings with the patient, including potential targeted therapies or clinical trial opportunities based on the identified mutations. Follow-up appointments may be scheduled to assess the patient's response to treatment and to make any necessary adjustments based on ongoing evaluations.
| Short Descr | SO NEO GSAP 5-50DNA/DNA&RNA | Medium Descr | SOLID ORGAN NEOPLASM GSAP 5-50 DNA/DNA&RNA ALYS | Long Descr | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 |
| GZ | Item or service expected to be denied as not reasonable and necessary | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GC | This service has been performed in part by a resident under the direction of a teaching physician | GW | Service not related to the hospice patient's terminal condition | XP | Separate practitioner, a service that is distinct because it was performed by a different practitioner | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Changed | Short, Medium, and Long Descriptions changed. Guideline information changed. |
| 2023-01-01 | Changed | Code description changed. |
| 2016-01-01 | Changed | Description Changed |
| 2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.